News
Stay informed about the latest developments and achievements from TRICALS.
Subscribe to our newsletterAll news
news
October 22, 2024
Lighthouse II study finished recruitment phase with more than 400 participants
Read more
news
October 17, 2024
Innovations in ALS clinical trials through the TRICALS Academy
Read more
news
October 15, 2024
Your expert opinion wanted on ALS clinical trials
Read more
news
August 23, 2024
TRICALS Academy celebrates first anniversary
Read more
news
May 31, 2024
European Commission approves Tofersen as treatment for ALS-SOD1
Read more
news
May 22, 2024
Amylyx terminates open-label extension of the PHOENIX study
Read more
news
April 17, 2024
Meet the centre – Torino ALS Center (University of Torino)
Read more
news
April 5, 2024
Amylyx withdraws RELYVRIO/AMX0035 from U.S. and Canadian markets
Read more
news
March 28, 2024
Results of TUDCA-study: No effect of investigated compound
Read more
news
March 8, 2024
Amylyx: no effect after analyzing phase 3 study
Read more
news
February 27, 2024
Tofersen receives positive opinion from CHMP (EMA)
Read more
news
January 10, 2024
Results ADORE study: no effect of medication
Read more
news
December 22, 2023
34th International Symposium on ALS/MND
Read more
Optionele subtitel van deze CTA
Titel CTA
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nunc vulputate libero et velit interdum, ac aliquet odio mattis. Class aptent taciti sociosqu ad litora torquent per conubia nostra, per inceptos himenaeos. Curabitur tempus urna at turpis condimentum lobortis.